Skip to main content
. 2026 Apr 1;25:59. doi: 10.1186/s12938-026-01564-z

Table 3.

Clinical and demographic characteristics of participants, categorized by PAD and non-PAD subjects. For continuous variables, mean ± standard deviation is shown. For categorical variables, the number of subjects and their percentage of the total number of subjects in the group are presented

Factor Non-PAD
(n = 118)
PAD
(n = 118)
p-value (Mann–Whitney U test)
HTN (n,%) 65 (55%) 84 (71%)
DBT duration (yarr) 10.8 ± 9.5 13.5 ± 8.4 0.002
HTN duration (year) 5.4 ± 6.9 8.0 ± 8.5 0.009
Comorbiditiesa (n, %) 43, 36% 48, 41%
Hyperlipidemia (n, %) 71, 60% 84, 71%
UIcers (n, %) 0, 0% 23, 19%
Claudication duration (year) 4.3 ± 3.9
Male (n, %) 52, 44% 50, 42%
Female (n, %) 66, 56% 68, 58%
Age (yr) 54.8 ± 13.7 59.1 ± 7.9 0.016
BMI (kg/m2) 30.3 ± 5.9 31.7 ± 5.5 0.071
Left ankle-brachial index 1.09 ± 0.08 0.88 ± 0.14  < 0.001
Right ankle-brachial index 1.10 ± 0.07 0.92 ± 0.11  < 0.001
Systolic blood pressure (mmHg) 136.51 ± 17.25 139.86 ± 11.89 0.478
Diastolic blood pressure (mmHg) 74.81 ± 9.88 72.43 ± 8.77 0.402
Tobacco use (n, %) 35, 30% 22, 19%
Anticoagulants (n, %) 12, 10% 14, 12%
Antiaggregants (n, %) 80, 68% 105, 89%
Statins (n, %) 70, 59% 75, 64%
Antihypertensive (n, %) 65, 55% 84, 71%

DBT diabetic, HTN hypertension, BMI body mass index

aComorbidities include myocardial infarction, coronary artery disease, cerebrovascular diseases, lung disease, lower limb revascularization.